Identified prognostic factors favouring the occurrence of severe neutropenia during treatment with FTD/TPI were time since diagnosis of the first metastasis of ≥18 months, absence of liver metastasis, age ≥ 70 years, presence of previous anti-VEGF treatment, previous lines of treatment > 2, baseline NLR < 5, baseline AST grade 0, baseline albumin ≥35 g/l, and baseline white blood cell count < 10 × 109/l (Supplementary Table 2). The gene discussed is VEGFA; the disease is neutropenia.